Morrisville, NC – According to filings with the U.S. Securities and Exchange Commission, Locus Biosciences is raising $20,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Paul Garofolo played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Locus Biosciences

We are a clinical-stage biotechnology company developing precision antimicrobial medicines for therapeutic indications across; infectious disease, immunology & oncology. Next generation CRISPR technology for programmed cell death. Focused on developing therapies for infectious disease and the microbiome.

To learn more about Locus Biosciences, visit http://www.locus-bio.com/

Contact:
Paul Garofolo, Chief Executive Officer
919-495-4510
paul.garofolo@locus-bio.com
https://www.linkedin.com/in/paulgarofolo/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved